文献速递淋巴瘤

非工程化多抗原靶向T细胞治疗淋巴瘤安全且产生持久临床效应

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
PubMed 文献 · J Clin Oncol · 2021-01-28

这项I期临床试验评估了靶向五种肿瘤相关抗原(PRAME、SSX2、MAGEA4、SURVIVIN、NY-ESO-1)的自体多克隆T细胞产品,在32例复发霍奇金或非霍奇金淋巴瘤患者中分两阶段进行:第一阶段确定同时靶向五种抗原的安全性(固定剂量0.5×10^7 cells/m2),第二阶段确定最大耐受剂量。输注安全,未观察到剂量限制性毒性,未达到最大耐受剂量,但确定推荐II期剂量为两次输注2×10^7 cells/m2。在化疗难治性患者中,7例霍奇金淋巴瘤中有2例、8例非霍奇金淋巴瘤中有4例达到持久完全缓解(>3年)。

要点

  • 靶向五种TAA的自体T细胞产品在淋巴瘤患者中安全,无剂量限制性毒性。
  • 推荐II期剂量为两次输注2×10^7 cells/m2。
  • 化疗难治性患者中观察到持久完全缓解(>3年)。

核心结论

  • 靶向五种TAA的T细胞产品在淋巴瘤患者中耐受良好,并在化疗难治性队列中显示初步抗淋巴瘤活性。

研究设计与样本

  • 两阶段I期临床试验,纳入32例复发霍奇金淋巴瘤(n=14)或非霍奇金淋巴瘤(n=18)患者。
  • 第一阶段确定同时靶向五种TAA的安全性(固定剂量0.5×10^7 cells/m2),第二阶段确定最大耐受剂量。
  • 患者既往接受中位三线治疗,入组时高危复发(辅助臂,n=17)或化疗难治(n=15)。

主要发现

  • 输注安全,在抗原递增和剂量递增阶段均未观察到剂量限制性毒性。
  • 未达到最大耐受剂量,确定推荐II期剂量为两次输注2×10^7 cells/m2(观察到疗效的最大测试剂量)。
  • 化疗难治性淋巴瘤患者中,7例霍奇金淋巴瘤有2例、8例非霍奇金淋巴瘤有4例达到持久完全缓解(>3年)。

关键数值与推荐

  • 固定剂量0.5×10^7 cells/m2用于第一阶段安全性评估。
  • 推荐II期剂量为两次输注2×10^7 cells/m2。
  • 持久完全缓解定义为>3年。

临床怎么用

  • 对于复发淋巴瘤患者,尤其是化疗难治性患者,多抗原靶向T细胞治疗可能是一种安全且有效的选择。
  • 推荐II期剂量为两次输注2×10^7 cells/m2,可在临床试验中进一步评估。

局限性

  • 样本量较小(32例),需要更大规模研究验证。
  • 未达到最大耐受剂量,最高测试剂量可能不是真正的最大耐受剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with relapsed lymphomas often fail salvage therapies including high-dose chemotherapy and mono-antigen-specific T-cell therapies, highlighting the need for nontoxic, novel treatments. To that end, we clinically tested an autologous T-cell product that targets multiple tumor-associated antigens (TAAs) expressed by lymphomas with the intent of treating disease and preventing immune escape. PATIENTS AND METHODS: We expanded polyclonal T cells reactive to five TAAs: PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1. Products were administered to 32 patients with Hodgkin lymphomas (n = 14) or non-Hodgkin lymphomas (n = 18) in a two-part phase I clinical trial, where the objective of the first phase was to establish the safety of targeting all five TAAs (fixed dose, 0.5 × 107 cells/m2) simultaneously and the second stage was to establish the maximum tolerated dose. Patients had received a median of three prior lines of therapy and either were at high risk for relapse (adjuvant arm, n = 17) or had chemorefractory disease (n = 15) at enrollment. RESULTS: Infusions were safe with no dose-limiting toxicities observed in either the antigen- or dose-escalation phases. Although the maximum tolerated dose was not reached, the maximum tested dose at which efficacy was observed (two infusions, 2 × 107 cells/m2) was determined as the recommended phase II dose. Of the patients with chemorefractory lymphomas, two (of seven) with Hodgkin lymphomas and four (of eight) with non-Hodgkin lymphomas achieved durable complete remissions (> 3 years). CONCLUSION: T cells targeting five TAAs and administered at doses of up to two infusions of 2 × 107 cells/m2 are well-tolerated by patients with lymphoma both as adjuvant and to treat chemorefractory lymphoma. Preliminary indicators of antilymphoma activity were seen in the chemorefractory cohort across both antigen- and dose-escalation phases.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vasileiou S, Lulla PD, Tzannou I, et al. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021. PMID: 33507803. doi:10.1200/JCO.20.02224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。